Crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
A novel crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy -pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same are disclosed. Processes for the preparation thereof and methods for use thereof are also disclosed.
1. A crystalline form of anhydrous sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide is characterized by an X-ray powder diffraction pattern comprising at least three diffraction angles, when measured using Cu K α radiation, selected from the group consisting of: 4.7, 9.1, 12.0, 14.2, 17.7, 18.1, 19.2, 19.8, 20.1, 21.3, 22.5, 24.3, 27.0, 27.2, 27.7, 28.6, 28.8, 29.0, 30.1, 31.6, 33.5, 33.6, and 37.6 degrees 2θ±0.2 degrees 2θ.
2. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising at least three diffraction angles selected from the group consisting of: 4.7, 9.1, 12.0, 14.2, 18.1, 19.2, 19.8, 20.1, 21.3, 22.5, 24.3, 27.2, 28.8, and 37.6 degrees 2θ±0.2 degrees 2θ.
3. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising at least three diffraction angles selected from the group consisting of: 4.7, 12.0, 14.2, 18.1, 19.2, and 24.3 degrees 2θ±0.2 degrees 2θ.
4. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 3 .
5. The crystalline form of claim 1 , wherein the crystalline form is characterized by a Raman spectrum comprising at least three peaks at positions selected from the group consisting of: 601, 632, 651, 664, 726, 740, 803, 853, 931, 1080, 1123, 1138, 1162, 1318, 1395, 1458, 1526, 1595, 1614, and 1647 cm −1 ±4 cm −1 .
6. The crystalline form of claim 5 , wherein the crystalline form is characterized by a Raman spectrum comprising at least three peaks at positions selected from the group consisting of: 664, 740, 803, 853, 1080, 1123, 1162, 1318, 1458, 1526, 1595, 1614, and 1647 cm −1 ±4 cm −1 .
7. The crystalline form of claim 5 , wherein the crystalline form is characterized by a Raman spectrum comprising at least three peaks at positions selected from the group consisting of: 664, 1162, 1458, 1614, and 1647 cm −1 ±4 cm −1 .
8. The crystalline form of claim 5 , wherein the crystalline form is characterized by a Raman spectrum comprising at least three peaks at positions selected from the group consisting of 664, 740, 803, 853, 1080, 1123, 1162, 1318, 1458, 1526, 1595, 1614, and 1647 cm −1 ±4 cm −1 .
9. The crystalline form of claim 1 , wherein said crystalline form is characterized by a Raman spectrum substantially in accordance with FIG. 6 .
10. The crystalline form of claim 1 , wherein the crystalline form differential scanning calorimetry themogram profile is substantially in accordance with FIG. 8 .
11. The crystalline form of claim 1 , wherein the crystalline form thermogravimetric analysis trace is substantially in accordance with FIG. 10 .
12. A pharmaceutical composition comprising the crystalline form according to claim 1 and a pharmaceutically acceptable carrier.
13. The composition of claim 12 wherein the composition is adapted for oral administration.
14. The composition of claim 12 wherein the composition is in a form of a tablet or capsule.
15. A method of treating a CCR9-mediated disorder in a subject in need thereof comprising administering to the subject an effective amount of the crystalline form of claim 1 .
16. The method of claim 15 wherein the CCR9-mediated disorder is an inflammatory bowel disease.
17. The method of claim 16 wherein the inflammatory bowel disease is selected from Crohn's disease and ulcerative colitis.